All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @iamalexissolia on TikTok · 84s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @iamalexissolia's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Everyone always says there's no difference between oral ischions and the other forms of
  2. 0:04ischrogens.
  3. 0:05Taking pills is just like taking gels and patches and injections.
  4. 0:09That is not true.
  5. 0:11When you take pills, you're putting your body through something completely different compared
  6. 0:15to when you take patches, injections and gels.
  7. 0:18Even if you still take your pills sublingually by dissolving underneath your tongue as you
  8. 0:22should, your pill is still going through your digestive tract.
  9. 0:26I guess metabolized bio-lever completely transforming how your blood actually clots.
  10. 0:31That's why oral ischions lead to a high risk of strokes, even thrombosis, pulmonary embolism,
  11. 0:36clots and cardiovascular stress.
  12. 0:39That's why it's specifically important to be more cautious when you're increasing your
  13. 0:43ischion dosage specifically when you're an oral ischion.
  14. 0:46Because the more oral ischion you take, the more you increase your chances of developing
  15. 0:50these conditions.
  16. 0:51So please don't let anybody tell you that it's all the same because it's not.
  17. 0:55If you're on HRT or thinking about starting HRT, I also want to learn how I grew my chest
  18. 0:59from being flatter spankase to double-dese without any surgery, without any implants,
  19. 1:05doing it just by taking hormones.
  20. 1:07You want to learn about breast development, hormone roots, how to work with your body rather
  21. 1:11than against it.
  22. 1:12Take a look at my ebook growing my chest on HRT from pancakes to double-dese where I
  23. 1:16go through my journey on HRT and how I grew my chest, no surgery, no fluff.
  24. 1:22And better, bye!

@iamalexissolia's estrogen delivery claims, fact-checked

iamalexissolia

TikTok creator

24.8K viewsWatch on TikTok

Quick answer

Oral estrogens undergo hepatic first-pass metabolism, increasing synthesis of coagulation factors including factor VII and fibrinogen, which elevates venous thromboembolism risk compared to transdermal delivery. The ESTHER study (Canonico et al., 2007) found a fourfold VTE risk increase with oral estrogen versus no significant increase with transdermal estrogen. Sublingual estradiol largely bypasses first-pass metabolism and is not pharmacologically equivalent to swallowed oral estrogen, contrary to the claim made in this video.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

TRT social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @iamalexissolia's estrogen delivery claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

@iamalexissolia's estrogen delivery claims, fact-checked should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Claim path

Keep researching this testosterone and trt video claims cluster

Best for searchers turning TRT social claims into a safer lab-backed provider discussion.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@iamalexissolia's estrogen delivery claims, fact-checked" from iamalexissolia. We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Oral estrogens undergo hepatic first-pass metabolism, increasing synthesis of coagulation factors including factor VII and fibrinogen, which elevates venous thromboembolism risk compared to transdermal delivery.

The reason this review is not generic is the source wording and the canonical claim label "trt not all estrogen is the same and your body knows it oral." In this clip, the useful excerpt is: "Everyone always says there's no difference between oral ischions and the other forms of ischrogens." That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Cardiovascular Safety of Testosterone-Replacement Therapy (2023), Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline (2010), and Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies (2026), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Transdermal estrogen bypasses hepatic first-pass metabolism, meaning it does not trigger the same increases in clotting factors like fibrinogen and factor VII that oral estrogen does.
People who land here are usually comparing the Testosterone claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Testosterone guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Oral estrogens undergo hepatic first-pass metabolism, increasing synthesis of coagulation factors including factor VII and fibrinogen, which elevates venous thromboembolism risk compared to transdermal delivery.

FormBlends verdict

Testosterone evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Oral estrogens undergo hepatic first-pass metabolism, increasing synthesis of coagulation factors including factor VII and fibrinogen, which elevates venous thromboembolism risk compared to transdermal delivery. The ESTHER study (Canonico et al., 2007) found a fourfold VTE risk increase with oral estrogen versus no significant increase with transdermal estrogen. Sublingual estradiol largely bypasses first-pass metabolism and is not pharmacologically equivalent to swallowed oral estrogen, contrary to the claim made in this video.
  • The ESTHER study (Canonico et al., 2007, Circulation) found a fourfold increased VTE risk with oral estrogen compared to non-users, while transdermal estrogen showed no statistically significant increase.
  • Transdermal estrogen bypasses hepatic first-pass metabolism, meaning it does not trigger the same increases in clotting factors like fibrinogen and factor VII that oral estrogen does.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • The ESTHER study (Canonico et al., 2007, Circulation) found a fourfold increased VTE risk with oral estrogen compared to non-users, while transdermal estrogen showed no statistically significant increase.
  • Transdermal estrogen bypasses hepatic first-pass metabolism, meaning it does not trigger the same increases in clotting factors like fibrinogen and factor VII that oral estrogen does.
  • Sublingual estradiol largely bypasses first-pass metabolism and is pharmacologically distinct from swallowed oral estradiol. The video's claim that sublingual pills still go through the liver is incorrect.
  • Absolute clot risk from oral estrogen is not uniform. It is significantly higher in people with pre-existing risk factors such as obesity, smoking, thrombophilia, or factor V Leiden mutations.
  • Current Endocrine Society guidelines recommend transdermal estrogen as the preferred route for patients with elevated cardiovascular or thromboembolic risk.
  • The creator's broad conclusion that routes are not equivalent is scientifically sound, but the framing strips out individual risk stratification that a clinician would consider before recommending any route change.
  • No route-of-administration preference should be acted on without an individual clinical assessment. This video is not a substitute for that evaluation.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @iamalexissolia actually say?

The creator's core argument is that oral estrogen and non-oral forms like patches, gels, and injections are not interchangeable, and that taking pills exposes you to higher risks of blood clots, stroke, DVT, and pulmonary embolism. They also claim that sublingual dosing still routes through the digestive tract and liver, and that higher oral doses compound these risks. That last point about sublingual absorption is factually wrong, but the broader clot-risk argument has real clinical backing.

The video is aimed at a transgender HRT audience, which is worth noting because baseline cardiovascular risk profiles in that population differ from postmenopausal women, where most of the foundational research was conducted. The creator doesn't acknowledge that distinction at all.

Does the science back this up?

On the main claim, yes, with caveats. The first-pass hepatic metabolism of oral estrogen is well-documented, and its effect on coagulation factors is not seriously disputed in the literature.

The ESTHER study (Canonico et al., 2007, Circulation) is the landmark reference here. It found that oral estrogen was associated with a fourfold increased risk of venous thromboembolism compared to non-users, while transdermal estrogen showed no statistically significant increase. A 2016 meta-analysis by Sweetland et al. in the British Medical Journal reinforced this, finding oral routes consistently elevated clot risk while transdermal routes did not. The mechanism is well understood: oral estrogens increase hepatic synthesis of clotting factors, particularly factor VII and fibrinogen, while transdermal delivery bypasses this entirely by entering systemic circulation directly.

So the creator is pointing at something real. The problem is the framing, which is absolute and strips out important nuance around individual risk stratification.

What did they get wrong (or right)?

Let's start with the sublingual claim, because it's a clear error. The creator says that even dissolving a pill under your tongue means it "still goes through your digestive tract." That is incorrect. Sublingual absorption bypasses first-pass hepatic metabolism precisely because the sublingual mucosa delivers the drug directly into venous circulation. This is not a minor detail. It's the entire reason sublingual estradiol is sometimes used as an alternative to patches or injections in clinical practice.

On the broader clot risk claim, the creator gets the direction right but overstates the certainty. Phrases like "oral estrogen leads to a high risk of strokes" present this as a guaranteed outcome rather than a probabilistic one that depends heavily on baseline risk factors, dose, formulation, and duration. A healthy 25-year-old on low-dose oral estradiol does not have the same absolute risk as a 55-year-old with a clotting disorder. The creator doesn't mention any of this.

What they got right: the hepatic first-pass distinction is real, the coagulation mechanism is real, and the clinical preference for transdermal routes in higher-risk patients is supported by current guidelines, including those from the Endocrine Society.

What should you actually know?

Route of administration matters, but your individual risk profile matters more. The evidence for transdermal estrogen carrying lower VTE risk is solid, particularly in populations with pre-existing clotting risk factors, obesity, smoking history, or factor V Leiden mutations. For people without those risk factors, the absolute risk difference between oral and transdermal routes is small, though not zero.

Sublingual estradiol occupies a legitimate middle ground in practice. Because it largely bypasses first-pass metabolism, its hepatic impact is closer to transdermal than to oral, though the pharmacokinetics are less predictable and peak levels can be variable (Wierckx et al., 2014, Journal of Sexual Medicine).

If you're on HRT or considering it, the conversation about route of administration belongs with a licensed clinician who can assess your actual cardiovascular and coagulation risk. This video is not that assessment. The creator is selling an ebook at the end, which does not disqualify the science they cite, but it's context worth having.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

iamalexissolia · TikTok creator

24.8K views on this video

Not all estrogen is the same. And your body knows it. Oral estrogen goes through your liver first. That can increase the risk of things like blood clots, DVT, pulmonary embolism, and stroke for some

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the esther study (canonico et al., 2007, circulation) found a?

The ESTHER study (Canonico et al., 2007, Circulation) found a fourfold increased VTE risk with oral estrogen compared to non-users, while transdermal estrogen showed no statistically significant increase.

What does the video say about transdermal estrogen bypasses hepatic first-pass metabolism, meaning it does not?

Transdermal estrogen bypasses hepatic first-pass metabolism, meaning it does not trigger the same increases in clotting factors like fibrinogen and factor VII that oral estrogen does.

What does the video say about sublingual estradiol largely bypasses first-pass metabolism?

Sublingual estradiol largely bypasses first-pass metabolism and is pharmacologically distinct from swallowed oral estradiol. The video's claim that sublingual pills still go through the liver is incorrect.

What does the video say about absolute clot risk from?

Absolute clot risk from oral estrogen is not uniform. It is significantly higher in people with pre-existing risk factors such as obesity, smoking, thrombophilia, or factor V Leiden mutations.

What does the video say about current endocrine society guidelines recommend transdermal estrogen as the preferred?

Current Endocrine Society guidelines recommend transdermal estrogen as the preferred route for patients with elevated cardiovascular or thromboembolic risk.

What does the video say about the creator's broad conclusion?

The creator's broad conclusion that routes are not equivalent is scientifically sound, but the framing strips out individual risk stratification that a clinician would consider before recommending any route change.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by iamalexissolia, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.